P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding

P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding

Dual antiplatelet therapy comprising of aspirin and oral P2Y12 receptor antagonists are an established cornerstone of therapy in acute coronary syndromes and percutaneous coronary intervention. As a result, the platelet P2Y12 receptor remains a key therapeutic target in cardiovascular medicine since...

Full description

Bibliographic Details
Main Authors: Himawan Fernando, James D. McFadyen, Xiaowei Wang, James Shaw, Dion Stub, Karlheinz Peter
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
P2Y12 receptor
P2Y12 receptor antagonists
platelet receptors
antithrombotic therapy
myocardial infarction
percutaneous coronary intervention
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.854813/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.854813/full

Similar Items